NeuroDerm Ltd - Product Pipeline Analysis, 2018 Update

Summary

NeuroDerm Ltd (NeuroDerm), a subsidiary of Mitsubishi Tanabe Pharma Corp, is a pharmaceutical company that develops of drugs for the treatment of Parkinsons disease and central nervous system (CNS) disorders through proprietary reformulations of its existing drugs. The companys liquid formulation of levodopa/carbidopa product candidates includes ND0612L, intended for moderate Parkinsons diseases; and ND0612H, for severe Parkinsons disease. It also develops ND0701, intended for patients with severe Parkinsons disease and ND0801, a product candidate intended for the treatment of cognitive disorders associated with CNS diseases including attention deficit disorder or attention deficit hyperactivity disorder, schizophrenia, alzheimers disease, and other diseases. NeuroDerm is headquartered in Rehovot, Israel.

This report is a source for data, analysis, and actionable intelligence on the companys portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company NeuroDerm Ltd
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio



List of Tables 4
List of Figures 4
NeuroDerm Ltd Company Overview 5
NeuroDerm Ltd Company Snapshot 5
NeuroDerm Ltd Pipeline Products and Ongoing Clinical Trials Overview 5
NeuroDerm Ltd Pipeline Analysis Overview 7
NeuroDerm Ltd - Key Facts 7
NeuroDerm Ltd - Major Products and Services 8
NeuroDerm Ltd Pipeline Products by Development Stage 9
NeuroDerm Ltd Ongoing Clinical Trials by Trial Status 11
NeuroDerm Ltd Pipeline Products Overview 13
CRONO ND 13
CRONO ND Product Overview 13
CRONO Twin ND 14
CRONO Twin ND Product Overview 14
CRONO Twin ND Clinical Trial 15
ND0601 Dermal Patch 16
ND0601 Dermal Patch Product Overview 16
ND0611 Dermal Patch 17
ND0611 Dermal Patch Product Overview 17
ND0612H Belt Pump 18
ND0612H Belt Pump Product Overview 18
ND0612L Patch Pump 19
ND0612L Patch Pump Product Overview 19
ND0612L Patch Pump Clinical Trial 20
ND0901 21
ND0901 Product Overview 21
NeuroDerm Ltd - Key Competitors 22
NeuroDerm Ltd - Key Employees 23
NeuroDerm Ltd - Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
NeuroDerm Ltd, Recent Developments 25
Aug 03, 2017: NeuroDerm Announces Second Quarter 2017 Financial Results 25
Jun 27, 2017: Results of NeuroDerms ND0612H Phase II Trial Presented in Oral Session at the 3rd Congress of the European Academy of Neurology 25
Jun 08, 2017: NeuroDerm Presents Six Posters at the 21st International Congress of Parkinsons Disease and Movement Disorders 26
Jun 06, 2017: European Medicines Agency Accepts Design of NeuroDerms ND0612 Phase III iNDiGO Efficacy Trial 28
Jun 05, 2017: NeuroDerm Presents ND0612H Phase II Trial Results in Late-Breaking Poster Session at the 21st International Congress of Parkinsons Disease and Movement Disorders 28
May 23, 2017: NeuroDerm ND0612H Phase II Trial Results to be Presented in Late-Breaking Session at the 21st International Congress of Parkinsons Disease and Movement Disorders 30
May 11, 2017: NeuroDerm Announces First Quarter 2017 Financial Results 30
Mar 30, 2017: NeuroDerm Announces Fourth Quarter and Full Year 2016 Financial Results 31
Mar 01, 2017: NeuroDerm Achieves Primary Endpoint in ND0612H Phase II Trial for Advanced Parkinsons Disease; Seeks Broader EU Label Based on iNDiGO Trial Following EMA Meeting 33
Dec 22, 2016: NeuroDerm Announces Completion of Patient Enrollment and Treatment in a Phase II Trial of ND0612H for Advanced Parkinsons Disease 35
Appendix 36
Methodology 36
About GlobalData 39
Contact Us 39
Disclaimer 39

List Of Tables


NeuroDerm Ltd Pipeline Products and Ongoing Clinical Trials Overview 5
NeuroDerm Ltd Pipeline Products by Equipment Type 6
NeuroDerm Ltd Pipeline Products by Indication 6
NeuroDerm Ltd Ongoing Clinical Trials by Trial Status 6
NeuroDerm Ltd, Key Facts 7
NeuroDerm Ltd, Major Products and Services 8
NeuroDerm Ltd Number of Pipeline Products by Development Stage 9
NeuroDerm Ltd Pipeline Products Summary by Development Stage 10
NeuroDerm Ltd Ongoing Clinical Trials by Trial Status 11
NeuroDerm Ltd Ongoing Clinical Trials Summary 12
CRONO ND - Product Status 13
CRONO ND - Product Description 13
CRONO Twin ND - Product Status 14
CRONO Twin ND - Product Description 14
CRONO Twin ND - A Multicenter, International, Open-label, Safety Study of ND0612, a Solution of Levodopa/carbidopa Delivered via a Pump System as a Continuous Subcutaneous Infusion in Subjects with Advanced Parkinsons Disease 15
CRONO Twin ND - A Phase III Randomized, Open-Label, Multi-center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-based Chemotherapy in First Line Treatment of Patients with Advanced or Metastatic Non Small-cell Lung Cancer (NSCLC): MYSTIC 15
ND0601 Dermal Patch - Product Status 16
ND0601 Dermal Patch - Product Description 16
ND0611 Dermal Patch - Product Status 17
ND0611 Dermal Patch - Product Description 17
ND0612H Belt Pump - Product Status 18
ND0612H Belt Pump - Product Description 18
ND0612L Patch Pump - Product Status 19
ND0612L Patch Pump - Product Description 19
ND0612L Patch Pump - A Follow-up Comparison Pharmacokinetic Study of ND-0701 (Apomorphine) 20
ND0901 - Product Status 21
ND0901 - Product Description 21
NeuroDerm Ltd, Key Employees 23
Glossary 38

List Of Figures


NeuroDerm Ltd Pipeline Products by Equipment Type 6
NeuroDerm Ltd Pipeline Products by Development Stage 9
NeuroDerm Ltd Ongoing Clinical Trials by Trial Status 11

NeuroDerm Ltd - Product Pipeline Analysis, 2018 Update

NeuroDerm Ltd (NeuroDerm), a subsidiary of Mitsubishi Tanabe Pharma Corp, is a pharmaceutical company that develops of drugs for the treatment of Parkinsons disease and central nervous system (CNS) disorders

USD 750 View Report

NeuroDerm Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

NeuroDerm Ltd (NeuroDerm), a subsidiary of Mitsubishi Tanabe Pharma Corp, is a pharmaceutical company that develops of drugs for the treatment of Parkinsons disease and central nervous system (CNS) disorders

USD 250 View Report

Investec Asset Management Ltd - Strategic SWOT Analysis Review

Investec Asset Management Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis,

USD 125 View Report

NR Electric Co Ltd - Strategic SWOT Analysis Review

NR Electric Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis,

USD 125 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available